Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 11/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094288 | 0.84 | SLC29A1 (0.72) | SLC29A1CYP2C19PRUNE1CCNE2CCNE1 | |
| Hydrochloric Acid SCHEMBL17494537 | 0.83 | SLC29A1 (0.70) | SLC29A1CYP2C19PRUNE1CCNE2CCNE1 | |
| SCHEMBL16094477 | 0.79 | SLC29A1 (0.44) | SLC29A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL16094563 | 0.79 | SLC29A1 (0.46) | SLC29A1CYP1A2CYP2C19CRHR1 | |
| SCHEMBL16094704 | 0.78 | SLC29A1 (0.51) | SLC29A1CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL16094696 | 0.77 | SLC29A1 (0.50) | SLC29A1CYP1A2CYP2C19 | |
| SCHEMBL16094551 | 0.76 | SLC29A1 (0.43) | SLC29A1CYP1A2CYP2C19 | |
| SCHEMBL16094717 | 0.75 | SLC29A1 (0.55) | SLC29A1PRUNE1 | |
| SCHEMBL16094604 | 0.75 | SLC29A1 (0.48) | SLC29A1CYP1A2CYP2C19KCNH3TLR8 | |
| SCHEMBL14511435 | 0.74 | CYP1A2 (0.40) | SLC29A1CYP1A2CYP2C19CRHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643971-B2 | Breathing control modulating compounds, and methods of using same | GALLEON PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | claimed |
| US-9643971-B2 | Breathing control modulating compounds, and methods of using same | GALLEON PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2968329-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151462-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | PRDX5, QDPR, P2RX5 | SLC29A1 1696/4885CYP1A2 1766/4885CYP2C19 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.